Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
9004-66-4
Molecular formula
Not available
Molecular weight
Not available
Drug class
Intravenous iron(III)-dextran complexparenteral iron replacement agent
Mechanism of action
A colloidal iron(III)-hydroxide core complexed with dextran. After administration, iron is taken up by reticuloendothelial cells and released for transferrin binding and incorporation into haemoglobin and iron stores; it is not a simple dissociating iron salt.
Indications / reported uses
Treatment of documented iron deficiency in adults and paediatric patients aged 4 months and older who cannot tolerate oral iron or have had an unsatisfactory response to oral iron; formulation-specific test-dose and hypersensitivity precautions apply
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Iron Dextran PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Iron Dextran Permitted Daily Exposure (PDE) report (the Iron Dextran PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Iron Dextran Occupational Exposure Limit (OEL) report (the Iron Dextran OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.